Trishula Therapeutics is developing TTX-030, a first-in-class anti-CD39 antibody that targets immune evasion mechanisms in the tumor microenvironment to enhance anti-tumor immune responses. This approach aims to prevent immune suppression caused by extracellular adenosine, thereby improving treatment outcomes for patients with metastatic pancreatic cancer and other solid tumors.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers evade the immune system by creating a suppressive tumor microenvironment. This environment is often characterized by high levels of extracellular adenosine, which inhibits anti-tumor immune responses. Current cancer treatments may not effectively address this immune evasion mechanism.
Solution
Trishula Therapeutics is developing TTX-030, a first-in-class anti-CD39 antibody designed to disrupt immune evasion within the tumor microenvironment. By targeting CD39, TTX-030 aims to prevent the production of immunosuppressive adenosine, thereby enhancing the body's natural anti-tumor immune responses. This approach has the potential to improve treatment outcomes for patients with metastatic pancreatic cancer and other solid tumors by making the tumor microenvironment more conducive to immune attack. TTX-030 is currently undergoing a randomized Phase 2 study in frontline metastatic pancreatic cancer.
Target Audience
The primary target audience includes patients with metastatic pancreatic cancer and other solid tumors, as well as oncologists and researchers focused on immuno-oncology.
Features
- First-in-class anti-CD39 antibody
- Targets the production of extracellular adenosine in the tumor microenvironment
- Enhances anti-tumor immune responses
- Designed to overcome immune suppression caused by adenosine
- Studied in Phase 1/1b clinical studies in multiple solid tumors
- Currently in a randomized Phase 2 study for first-line metastatic pancreatic cancer